Table 1.
Patient characteristics
| Characteristics | Data |
|---|---|
| Age, median, years (range) | 56 (27–76) |
| Male/female, n | 13/7 |
| Hematological malignancy, n (%) | |
| Acute lymphoid leukemia | 1 (5) |
| Acute myeloid leukemia | 2 (10) |
| Mixed phenotype acute leukemia | 1 (5) |
| Chronic lymphoid leukemia | 4 (20) |
| Diffuse large B-cell lymphoma | 4 (20) |
| Follicular lymphoma | 2 (10) |
| Mantle cell lymphoma | 3 (15) |
| Splenic marginal zone lymphoma | 1 (5) |
| Myelofibrosis | 1 (5) |
| Multiple myeloma | 1 (5) |
| Disease status, n (%) | |
| Complete remission | 9 (45) |
| Partial remission | 3 (15) |
| Progressive disease | 8 (40) |
| Previous lines of therapy, median, n (range) | 1 (0–5) |
| Previous treatment with anti-CD20 therapy, n (%) | |
| Rituximab | 10 (50) |
| Obinutuzumab | 3 (15) |
| None | 7 (35) |
| Last chemotherapy, n (%) | |
| Anti-CD20 + chemotherapy | 3 (15) |
| Anti-CD20 maintenance | 5 (25) |
| Classical chemotherapy | 4 (20) |
| Small molecule | 4 (20) |
| Treatment naive | 2 (10) |
| Other | 2 (10) |
| Hemopoietic stem cell transplantation, n (%) | |
| Autologous | 5 (25) |
| Allogenic | 1 (5) |
| None | 14 (70) |
| COVID-19 severity score (WHO), n (%) | |
| 4 | 8 (40) |
| 5 | 10 (50) |
| 6–7 | 0 |
| 8–9 | 2 (10) |
| COVID-19 specific treatments, n (%) | |
| Favipiravir | 9 (45) |
| Dexamethasone | 20 (100) |
| Tocilizumab | 0 |
| Bamlanivimab | 5 (25) |
| Days of remdesivir therapy | |
|
All patients, median, n (range) Short course (8–10 days), n (%) Intermediate course (11–20 days), n (%) Long course (21–30 days), n (%) |
12.5 (8–30) 4 (20) 14 (70) 2 (10) |
| Convalescent plasma units, median, n (range) | 4 (1–15) |
| Simultaneous use of remdesivir and CP, n (%) | 17 (85) |
| COVID-19 vaccination, n (%) | 2 (10) |
| Time from…, median, days (range) | |
| Symptoms onset to PCR positivity | 3.5 (0–10) |
| Symptoms onset to antiviral therapy | 6.5 (1–21) |
| Symptoms onset to CP therapy | 13.5 (3–44) |
| PCR positivity to antiviral therapy | 1 (0–20) |
| PCR positivity to CP therapy | 7.5 (2–44) |
| PCR positivity to discharge (n = 19) | 22 (10–69) |
| PCR positivity to PCR negativity (n = 19) | 63 (6–204) |
| CP therapy to loss of oxygen dependency (n = 12) | 9.5 (2–36) |
| CP therapy to discharge (n = 19) | 16 (4–55) |
| CP therapy to PCR negativity (n = 19) | 59 (4–188) |
| Laboratory parameters | |
| Absolute neutrophil count, median, G/L (range) | 2.82 (0.27–9.25) |
| Absolute lymphocyte count, median, G/L (range) | 0.52 (0–5.44) |
| CD19 + B-cell count, cell/µL (range) | 0 (0–77.7) |
| CD4 + T-cell count, cell/µL (range) | 112 (18–1029) |
| CD8 + T-cell count, cell/µL (range) | 165 (5–501) |
| IgG, median, g/L (range) | 7.5 (0–14) |
| IgA, median, g/L (range) | 0.8 (0–2.3) |
| IgM median, g/L (range) | 0.21 (0–1.98) |
Small molecules include ibrutinib monotherapy (n = 3) and venetoclax plus acalabrutinib (n = 1). Other therapies include: venetoclax plus Obinutuzumab (n = 1) and ruxolitinib (n = 1)
WHO World Health Organization, CP convalescent plasma, PCR polymerase chain reaction, G giga, L liter, g gram, µ micro, Ig immunoglobulin